Although both metabolites are equivalent regarding ERα binding and inhibition of E2-induced cell proliferation, it is proposed that End is the principal antiestrogenic metabolite for the antitumour activity observed in breast cancer patients [49]. Here, ESR1 is linked to breast cancer.